The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.
View 10x Genomics, Inc. (TXG) current and estimated P/E ratio data provided by Seeking Alpha.
In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report). The company’s shares opened today at $14.74.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback